Cargando…

Clinical significance of 206 station lymph node in transverse colon cancer

BACKGROUND: Lymph node (LN) metastasis is crucial in determining the prognosis and treatment options for colon cancer patients. Our work was to study whether the lymph nodes beyond D3 station in transverse colon cancer, especially 206 LN, should be dissected. METHODS: A total of 225 patients within...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yu Xin, Huang, Ying, Wang, Xiao Jie, Ye, Dao Xiong, Chi, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189469/
https://www.ncbi.nlm.nih.gov/pubmed/35437894
http://dx.doi.org/10.1002/cam4.4626
_version_ 1784725597069508608
author Xu, Yu Xin
Huang, Ying
Wang, Xiao Jie
Ye, Dao Xiong
Chi, Pan
author_facet Xu, Yu Xin
Huang, Ying
Wang, Xiao Jie
Ye, Dao Xiong
Chi, Pan
author_sort Xu, Yu Xin
collection PubMed
description BACKGROUND: Lymph node (LN) metastasis is crucial in determining the prognosis and treatment options for colon cancer patients. Our work was to study whether the lymph nodes beyond D3 station in transverse colon cancer, especially 206 LN, should be dissected. METHODS: A total of 225 patients within our department were reviewed. The primary and secondary endpoints were overall survival (OS) and disease‐free survival (DFS). We employed Propensity score weighting (PSW) for weighing participants to balance observed confounders between the 206(D+) group and the 206(D−) group. RESULTS: The rate of metastasis in station 206 was 9.3%. Only T stage (OR, 3.009; 95% CI, 1.018–8.892), N stage (OR, 9.818; 95% CI, 1.158–83.227), and M stage (OR, 26.126; 95% CI, 1.274–535.945) were an independent risk factor for 206 station metastasis in multivariate logistic analysis. The 206(D+) group had a similarly survival than the 206(D−) group (3‐year DFS, 89.6% v 85.9%; p = 0.389; 3‐year OS, 94.6% v 85.3% p = 0.989). PSW further verified it. Metastasis of 206 station LN is not an independent prognostic factor, but a predictive factor of DFS. CONCLUSION: Station 206 LN positive is a predictive factor for DFS. Only the patient with T1‐3, N+ who is at a high risk of 206 station LN metastases should consider dissecting 206 station LN.
format Online
Article
Text
id pubmed-9189469
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91894692022-06-16 Clinical significance of 206 station lymph node in transverse colon cancer Xu, Yu Xin Huang, Ying Wang, Xiao Jie Ye, Dao Xiong Chi, Pan Cancer Med RESEARCH ARTICLES BACKGROUND: Lymph node (LN) metastasis is crucial in determining the prognosis and treatment options for colon cancer patients. Our work was to study whether the lymph nodes beyond D3 station in transverse colon cancer, especially 206 LN, should be dissected. METHODS: A total of 225 patients within our department were reviewed. The primary and secondary endpoints were overall survival (OS) and disease‐free survival (DFS). We employed Propensity score weighting (PSW) for weighing participants to balance observed confounders between the 206(D+) group and the 206(D−) group. RESULTS: The rate of metastasis in station 206 was 9.3%. Only T stage (OR, 3.009; 95% CI, 1.018–8.892), N stage (OR, 9.818; 95% CI, 1.158–83.227), and M stage (OR, 26.126; 95% CI, 1.274–535.945) were an independent risk factor for 206 station metastasis in multivariate logistic analysis. The 206(D+) group had a similarly survival than the 206(D−) group (3‐year DFS, 89.6% v 85.9%; p = 0.389; 3‐year OS, 94.6% v 85.3% p = 0.989). PSW further verified it. Metastasis of 206 station LN is not an independent prognostic factor, but a predictive factor of DFS. CONCLUSION: Station 206 LN positive is a predictive factor for DFS. Only the patient with T1‐3, N+ who is at a high risk of 206 station LN metastases should consider dissecting 206 station LN. John Wiley and Sons Inc. 2022-04-18 /pmc/articles/PMC9189469/ /pubmed/35437894 http://dx.doi.org/10.1002/cam4.4626 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Xu, Yu Xin
Huang, Ying
Wang, Xiao Jie
Ye, Dao Xiong
Chi, Pan
Clinical significance of 206 station lymph node in transverse colon cancer
title Clinical significance of 206 station lymph node in transverse colon cancer
title_full Clinical significance of 206 station lymph node in transverse colon cancer
title_fullStr Clinical significance of 206 station lymph node in transverse colon cancer
title_full_unstemmed Clinical significance of 206 station lymph node in transverse colon cancer
title_short Clinical significance of 206 station lymph node in transverse colon cancer
title_sort clinical significance of 206 station lymph node in transverse colon cancer
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189469/
https://www.ncbi.nlm.nih.gov/pubmed/35437894
http://dx.doi.org/10.1002/cam4.4626
work_keys_str_mv AT xuyuxin clinicalsignificanceof206stationlymphnodeintransversecoloncancer
AT huangying clinicalsignificanceof206stationlymphnodeintransversecoloncancer
AT wangxiaojie clinicalsignificanceof206stationlymphnodeintransversecoloncancer
AT yedaoxiong clinicalsignificanceof206stationlymphnodeintransversecoloncancer
AT chipan clinicalsignificanceof206stationlymphnodeintransversecoloncancer